JOURNAL ARTICLE

PolyPeptide Shares Surge Amid Takeover Interest From EQT, KKR.

  • Published In: Bloomberg.com, 2026. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Nair, Dinesh; Catelli, Allegra; Baigorri, Manuel 3 of 3

Abstract

The article focuses on the rising share price of PolyPeptide Group AG, a Swiss contract drugmaker specializing in synthetic peptides for metabolic conditions such as obesity and diabetes, amid reported private equity takeover interest. Shares surged to their highest level in over three years following indications that firms including EQT AB, KKR & Co., and Advent are considering a buyout, potentially in partnership with the company’s controlling shareholder, Swedish businessman Frederik Paulsen Jr. Analysts from Royal Bank of Canada suggest a leveraged buyout at a 30% premium could yield a 25% to 35% internal rate of return, though Paulsen may prefer to maintain his stake given recent stock recovery. PolyPeptide is undergoing a turnaround and expanding its manufacturing facilities across Europe, the US, and India. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2026/04, pN.PAG
  • Document Type:Article
  • Subject Area:Business and Management
  • Publication Date:2026
  • Accession Number:192965364
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.